Understanding the patient with epilepsy and seizures in the dental practice

Journal of the Canadian Dental Association

Volumn 73, Issue 1, 2007, Pages 71-76

  Aragon, Cecilia E ^a   Burneo, Jorge G ^a  

^a WESTERN UNIVERSITY   (Canada)

Author keywords

Dental care for chronically ill; Emergency treatment; Epilepsy physiopathology

Indexed keywords

ANTICONVULSIVE AGENT;

CHEMICALLY INDUCED DISORDER; CLASSIFICATION; DENTAL CARE; DRUG INTERACTION; EMERGENCY TREATMENT; EPILEPSY; HUMAN; METHODOLOGY; PATHOPHYSIOLOGY; PERIODONTAL DISEASE; REVIEW; TOOTH FRACTURE; XEROSTOMIA;

ANTICONVULSANTS; DENTAL CARE FOR CHRONICALLY ILL; DRUG INTERACTIONS; EMERGENCY TREATMENT; EPILEPSY; HUMANS; PERIODONTAL DISEASES; TOOTH FRACTURES; XEROSTOMIA;

EID: 33846917284     PISSN: 07098936     EISSN: 14882159     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. Tellez-Zenteno JF, Pondal-Sordo M, Matijevic S, Wiebe S. National and regional prevalence of self-reported epilepsy in Canada. Epilepsia 2004; 45(12):1623-9.
2. Burneo JG, Tellez-Zenteno J, Wiebe S. Understanding the burden of epilepsy in Latin America: a systematic review of its prevalence and incidence. Epilepsy Res 2005; 66(1):63-74.
3. Burneo JG, McLachlan RS. When should surgery be considered for the treatment of epilepsy? CMAJ 2005; 172(9):1175-7.
4. Proposal for revised classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia 1989; 30(4):389-99.
5. Scheinfeld N. Phenytoin in cutaneous medicine: its uses, mechanisms and side effects. Dermatol Online J 2003; 9(3):6.
6. Asconape JJ. Some common issues in the use of antiepileptic drugs. Semin Neurol 2002; 22(1):27-39.
7. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000; 342(5):314-9.
8. Noachtar S. Subdural electrodes in focal cortical dysplasia. Epileptic Disord 2003; 5(Suppl 2):S91-4.
9. Wiebe S, Blume WT, Girvin JP, Eliaziw M; Effectiveness and Efficiency of Surgery for Temporal Lobe Epilepsy Study Group. A randomized, controlled trial of surgery for temporal-lobe epilepsy. N Engl J Med 2001; 345(5):311-8.
10. McKhann GM 2nd, Bourgeois BF, Goodman RR. Epilepsy surgery: indications, approaches, and results. Semin Neurol 2002; 22(3):269-78.
11. Loring DW. Neuropsychological evaluation in epilepsy surgery. Epilepsia 1997; 38(Suppl 4):S18-23.
12. Morrell F, Whisler WW, Bleck TP. Multiple subpial transection: a new approach to the surgical treatment of focal epilepsy. J Neurosurg 1989; 70(2):231-9.
13. Devlin AM, Cross JH, Harkness W, Chong WK, Harding B, Vargha-Khadem F, and other. Clinical outcomes of hemispherectomy for epilepsy in childhood and adolescence. Brain 2003; 126(Pt 3):556-66.
14. Karolyhazy K, Kovacs E, Kivovics P, Fejerdy P, Aranyi Z. Dental status and oral health of patients with epilepsy: an epidemiologic study. Epilepsia 2003; 44(8):1103-8.
15. Karolyhazy K, Kivovics P, Fejerdy P, Aranyi Z. Prosthodontic status and recommended care of patients with epilepsy. J Prosthet Dent 2005; 93(2):177-82.
16. Pick L, Bauer J. [Dentistry and epilepsy]. Nervenarzt 2001; 72(12):946-9. [Article in German]
17. Buck D, Baker GA, Jacoby A, Smith D, Chadwick DW. Patients' experiences of injury as a result of epilepsy. Epilepsia 1997; 38(4):439-44.
18. Aragon CE, Burneo JG, Helman J. Occult maxillofacial trauma in epilepsy. J Contemp Dent Pract 2001; 2(4):26-32.
19. Mattson RH, Gidal BE. Fractures, epilepsy, and antiepileptic drugs. Epilepsy Behav 2004; 5(Suppl 2):S36-40.
20. Sato Y, Kondo I, Ishida S, Motooka H, Takayama K, Tomita Y, and others. Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy. Neurology 2001; 57(3):445-9.
21. Angelopoulos AP. Diphenylhydantoin gingival hyperplasia. A clinicopathological review. 1. Incidence, clinical features and histopathology. Dent J 1975; 41(2):103-6.
22. Angelopoulos AP. A clinicopathological review. Diphenylhydantoin gingival hyperplasia: 2. Aetiology, pathogenesis, differential diagnosis and treatment. Dent J 1975; 41(5):275-7, 283.
23. Stoopler ET, Sollecito TP, Greenberg MS. Seizure disorders: update of medical and dental considerations. Gen Dent 2003; 51(4):361-6.
24. Ogunbodede EO, Adamolekun B, Akintomide AO. Oral health and dental treatment needs in Nigerian patients with epilepsy. Epilepsia 1998; 39(6):590-4.
25. Li LM, Russo M, O'Donoghu MF, Duncan JS, Sander JW. Allergic skin rash with lamotrigine and concomitant valproate therapy: evidence for an increased risk. Arq Neuropsiquiatr 1996; 54(1):47-9.
26. Archarya S, Bussel JB. Hematologic toxicity of sodium valproate. Pediatr Hemat Oncol 2000; 22(1):62-5.
27. Mockenhaupt M, Messenheimer J, Tennisj P, Schlingmann J. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology 2005; 64(7):1134-8.
28. Hirsch LJ, Weintraub DB, Buchsbaum R, Spencer HT, Straka T, Hager M, and other. Predictors of lamotrigine-associated rash. Epilepsia 2006; 47(2):318-22.
29. Goulden KJ, Dooley JM, Camfield PR, Fraser AD. Clinical valproate toxicity induced by acetylsalicylic acid. Neurology 1987; 37(8):1392-4.
30. Patsalos PN, Frosher W, Pisani F, Van Rijn CM. The importance of drug interactions in epilepsy therapy. Epilepsia 2002; 43(4):365-85.
31. Miners JO. Drug interactions involving aspirin (acetylsalicylic acid) and salicylic acid. Clin Pharmacokinet 1989; 17(5):327-44.
32. Scott RA, Besag FM, Neville BG. Buccal midazolam and rectal diazepam for treatment of prolonged seizures in childhood and adolescence: a randomised trial. Lancet 1999; 353(9153):623-6.
33. Scott RC. Buccal midazolam as rescue therapy for seizures. Lancet Neurol 2005; 4(10):592-3.